Subependymal giant cell astrocytoma secondary prevention: Difference between revisions
Created page with "__NOTOC__ {{Subependymal giant cell astrocytoma}} {{CMG}}{{AE}}{{SR}} ==Reference== {{reflist|2}} Category:Disease Category:Types of cancer Category:Rare disease..." |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Subependymal giant cell astrocytoma}} | {{Subependymal giant cell astrocytoma}} | ||
{{CMG}}{{AE}}{{SR}} | |||
==Overview== | |||
==Secondary Prevention== | |||
Effective measures for the secondary prevention of subependymal giant cell astrocytoma include: | |||
*Brain imaging, preferably [[MRI|magnetic resonance imaging]] with and without contrast, should be performed every 1 to 3 years until the age of 25 years in every patient with [[tuberous sclerosis]]. | |||
*Follow-up [[MRI|magnetic resonance imaging]] may not be needed every 3 years, but intervals may be prolonged in the presence of a stable lesion and a stable patient. | |||
*Screening and follow-up scans frequency should be tailored according to various clinical factors. | |||
:*New onset of symptoms such as [[headache]], [[visual loss|visual complaints]], [[nausea]], [[vomiting]], or increase in [[seizure|seizure activity]] should trigger an earlier MRI scan. | |||
:*Similarly, a growing subependymal giant cell astrocytoma should prompt a more frequent clinical and radiological follow-up. | |||
==Reference== | ==Reference== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 22:55, 2 November 2015
|
Subependymal giant cell astrocytoma Microchapters |
|
Differentiating Subependymal Giant Cell Astrocytoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Subependymal giant cell astrocytoma secondary prevention On the Web |
|
American Roentgen Ray Society Images of Subependymal giant cell astrocytoma secondary prevention |
|
FDA on Subependymal giant cell astrocytoma secondary prevention |
|
CDC on Subependymal giant cell astrocytoma secondary prevention |
|
Subependymal giant cell astrocytoma secondary prevention in the news |
|
Blogs on Subependymal giant cell astrocytoma secondary prevention |
|
Risk calculators and risk factors for Subependymal giant cell astrocytoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Secondary Prevention
Effective measures for the secondary prevention of subependymal giant cell astrocytoma include:
- Brain imaging, preferably magnetic resonance imaging with and without contrast, should be performed every 1 to 3 years until the age of 25 years in every patient with tuberous sclerosis.
- Follow-up magnetic resonance imaging may not be needed every 3 years, but intervals may be prolonged in the presence of a stable lesion and a stable patient.
- Screening and follow-up scans frequency should be tailored according to various clinical factors.
- New onset of symptoms such as headache, visual complaints, nausea, vomiting, or increase in seizure activity should trigger an earlier MRI scan.
- Similarly, a growing subependymal giant cell astrocytoma should prompt a more frequent clinical and radiological follow-up.